Key Slides on Hepatitis B Pretreatment Evaluation

Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
Paul Y. Kwo, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.49 MB
Released: February 16, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Professor Graham Foster shares his approach to the management of hepatitis B in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: November 18, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Patients and expert faculty discuss HBV misconceptions and how they impact patient engagement in care, from Clinical Care Options (CCO)

person default Janet Afoakwah, MPH person default William Amiteye person default Bright Ansah Patricia D. Jones, MD, MSCR Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 14, 2022 Expired: November 13, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings